Correction: Tumor mutational burden and survival on immune checkpoint inhibition in >8000 patients across 24 cancer types 3 de March de 2025 by Journal for ImmunoTherapy of Cancer current issue
Correction: Peritumoral administration of IFN{beta} upregulated mesenchymal stem cells inhibits tumor growth in an orthotopic, immunocompetent rat glioma model 13 de February de 2025 by Journal for ImmunoTherapy of Cancer current issue
Correction: Novel banana lectin CAR-T cells to target pancreatic tumors and tumor-associated stroma 11 de February de 2025 by Journal for ImmunoTherapy of Cancer current issue
Correction: Associations of concomitant medications with immune-related adverse events and survival in advanced cancers treated with immune checkpoint inhibitors: a comprehensive pan-cancer analysis 31 de December de 2024 by Journal for ImmunoTherapy of Cancer current issue
Correction: Targeting CD93 on monocytes revitalizes antitumor immunity by enhancing the function and infiltration of CD8+ T cells 12 de November de 2024 by Journal for ImmunoTherapy of Cancer current issue
Correction: Inhibition of PNCK inflames tumor microenvironment and sensitizes head and neck squamous cell carcinoma to immune checkpoint inhibitors 9 de November de 2024 by Journal for ImmunoTherapy of Cancer current issue
Correction: Phase I studies of davoceticept (ALPN-202), a PD-L1-dependent CD28 co-stimulator and dual PD-L1/CTLA-4 inhibitor, as monotherapy and in combination with pembrolizumab in advanced solid tumors (NEON-1 and NEON-2) 16 de October de 2024 by Journal for ImmunoTherapy of Cancer current issue
Correction: ASCC3 promotes the immunosuppression and progression of non-small cell lung cancer by impairing the type I interferon response via CAND1-mediated ubiquitination inhibition of STAT3 10 de July de 2024 by Journal for ImmunoTherapy of Cancer current issue
Correction: Targeting SNORA38B attenuates tumorigenesis and sensitizes immune checkpoint blockade in non-small cell lung cancer by remodeling the tumor microenvironment via regulation of GAB2/AKT/mTOR signaling pathway 13 de May de 2024 by Journal for ImmunoTherapy of Cancer current issue
Correction: Total metabolic tumor volume on 18F-FDG PET/CT is a game-changer for patients with metastatic lung cancer treated with immunotherapy 27 de April de 2024 by Journal for ImmunoTherapy of Cancer current issue
Journal for ImmunoTherapy of Cancer current issue 